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Background and Purpose: Hypertensive vasculopathy and cerebral amyloid
angiopathy are the two most common forms of cerebral small vessel disease. Both
forms are associated with the development of primary intracerebral hemorrhage, but
the pathophysiological mechanisms underlying spontaneous vessel rupture remain
unknown. This work constitutes a systematic review on blood-brain barrier dysfunction
in the etiology of spontaneous intracerebral hemorrhage due to cerebral small vessel
disease.
Methods: We searched Medline (1946–2018) and Embase (1974–2018) for animal and
human studies reporting on blood-brain barrier dysfunction associated with intracerebral
hemorrhage or cerebral microbleeds.
Results: Of 26 eligible studies, 10 were animal studies and 16 were in humans.
The authors found indications for blood-brain barrier dysfunction in all four animal
studies addressing hypertensive vasculopathy-related intracerebral hemorrhage (n = 32
hypertensive animals included in all four studies combined), and in four of six
studies on cerebral amyloid angiopathy-related intracerebral hemorrhage (n = 47).
Of the studies in humans, five of six studies in patients with cerebral amyloid
angiopathy-related intracerebral hemorrhage (n = 117) and seven out of nine studies
examining intracerebral hemorrhage with mixed or unspecified underlying etiology
(n= 489) found indications for blood-brain barrier dysfunction. One post-mortem study in
hypertensive vasculopathy-related intracerebral hemorrhage (n = 82) found no evidence
for blood-brain barrier abnormalities.
Conclusions: Signs of blood-brain barrier dysfunction were found in 20 out of 26
studies. Blood-brain barrier integrity deserves further investigation with a view to
identification of potential treatment targets for spontaneous intracerebral hemorrhage.
Keywords: blood-brain barrier, intracerebral hemorrhage, cerebral small vessel disease, microbleeds, systematic
review
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INTRODUCTION
Spontaneous intracerebral hemorrhage (ICH) is the most
disabling and deadliest form of stroke (1), with an overall case
fatality of 40% at 1month, and 55% at 1 year (2, 3). Outcome after
ICH has seen little improvement over the past decades (2–4).
An important factor that has hampered development of specific
treatment and prevention strategies is the lack of knowledge
on pathophysiological processes underlying spontaneous
ICH. Hypertensive vasculopathy (HV) and cerebral amyloid
angiopathy (CAA), two distinct types of cerebral small vessel
disease (cSVD), are thought to be the most important causes
of spontaneous ICH (Box 1). In HV, degenerative alterations
in the vessel wall, including arteriosclerosis or atherosclerosis,
lipohyalinosis, and arteriolosclerosis affect the deep penetrating
small vessels in the brain (5, 7). This type of cSVD is usually
associated with ICH located in deep brain structures, including
the basal ganglia and thalamus, and in the posterior fossa and
brainstem (8). CAA is characterized by progressive deposition
of amyloid-β (Aβ) protein in the walls of small to medium
sized arteries (including arterioles) of the cerebral cortex and
leptomeninges (9), and is an important cause of lobar ICH
(6, 8).
A candidate key player in the pathophysiology of ICH is
the blood-brain barrier (BBB) (10, 11). The BBB is a term
used to describe the unique selective transport regulation
properties of the cerebral microvasculature (12). The BBB
is located along the microvascular endothelium and consists
of endothelial cells connected by tight junctions, which
restrict paracellular transport. Neighboring cell types include
astrocytes that ensheath the microvascular wall with their
endfeet, and pericytes that are embedded within the connective
Box 1 | De nitions of important terminology used throughout the paper.
Cerebral Small Vessel Disease: Umbrella term covering a variety
of pathological processes with various etiologies affecting the small
vessels (including arteries, arterioles, venules and capillaries) of the brain.
Hypertensive vasculopathy and cerebral amyloid angiopathy are the most
common forms.
Hypertensive Vasculopathy: The vascular phenotype of chronic
hypertension, including small vessel atherosclerosis, lipohyaliosis or fibrinoid
necrosis, and arteriolosclerosis (5), primarily affecting the deep penetrating
small vessels in the brain.
Cerebral Amyloid Angiopathy: Deposition of amyloid-beta in the walls of
the cerebrovasculature with preferential involvement of small arterioles and
capillaries of the leptomeninges and cerebral cortex, and a topographical
distribution favoring posterior lobar brain regions (6).
Spontaneous Intracerebral Hemorrhage: Nontraumatic
intraparenchymal bleeding due to spontaneous rupture of cerebral
vessels.
Cerebral Microbleeds: Radiological manifestations of small-vessel disease
which presumably correspond to small perivascular hemorrhages. Their
neuropathological equivalent, cerebral microhemorrhages, correspond
to erythrocyte extravasation or blood-breakdown products including
hematoidin or hemosiderin.
endothelial basement membrane. These cells, as part of
the neurovascular unit network that regulates local cerebral
blood flow, support and interact with the endothelial cells
and are essential for the induction and maintenance of the
BBB (13, 14). Upstream from capillaries, in arterioles, layers
of smooth muscle cells provide BBB support in addition
to other arteriolar constituents (15). Functions of the BBB
include the control of molecular traffic to exclude toxins,
maintenance of ion homeostasis, and control of immune
surveillance and response with minimal inflammation to protect
the neuronal environment (16). Previous research has led
to the hypothesis that BBB dysfunction may trigger HV-
type cSVD (17), and accumulating evidence also suggests
a pivotal role of BBB dysfunction in CAA-related vessel
pathology (18).
The objective of this systematic review is to summarize and
evaluate the currently available evidence from human and animal
studies to substantiate a potential role of BBB dysfunction in the
underlying vasculopathy of ICH. Cerebral microbleeds (CMBs),
as radiological imaging markers of cSVD and independent
predictors of future ICH (19, 20), may bear a pathophysiological
mechanism comparable to ICH (21). Therefore, we also included
studies that investigated BBB integrity in relation to CMBs
and their histological equivalent, cerebral microhemorrhages
(CMHs) (22).
MATERIALS AND METHODS
Literature Search Strategy
Studies were identified via a systematic search of MEDLINE
and EMBASE (MEDLINE 1946-March 8 2018, EMBASE 1974-
March 8 2018). The terms “intracerebral hemorrhage,” “cerebral
microbleed,” or “cerebral microhemorrhage” were entered in
combination with the term “blood-brain barrier” (Appendix S1).
Conference reports, case reports, reviews, and articles in
languages other than English were not included.
Inclusion/Exclusion Criteria
We included both human and animal studies investigating (1)
spontaneous ICH or CMBs/CMHs and (2) BBB dysfunction
preceding the hematoma in time or occurring spatially distant
to the hematoma. Exclusion criteria were artificially induced
hemorrhage (e.g., in experimental animal models by injection
of hemorrhage mimicking or inducing compounds), traumatic
ICH, hemorrhagic transformation of infarction, and secondary
ICH (due to rupture of an arteriovenous malformation, dural
arteriovenous fistula, cavernoma, tumor and others). We also
excluded reports that investigated perihematomal BBB leakage or
plasma markers of BBB dysfunction in the acute phase after ICH.
Selection of Studies and Data Extraction
One author (W.M.F.) performed title and abstract screening
to identify studies that were eligible for inclusion, and
subsequently reviewed full-text versions of these studies.
In case of uncertainty with regard to abstract and full-
text selection, studies were discussed with a second author
(C.J.M.K.). The reference lists of the included articles were
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screened but this did not lead to the inclusion of additional
papers. Data was extracted from all included studies by one
author (W.M.F.) and independently by two other authors
(F.H.B.M.S. and H.I.L.J.), who each extracted information
from half of the included studies, randomly distributed.
Discrepancies were resolved in consensus with the three authors
(W.M.F., F.H.B.M.S., H.I.L.J.). We extracted the following data:
(1) study type: animal/human, in vivo/post-mortem, cross-
sectional/longitudinal and retrospective/prospective design; (2)
hemorrhage type: ICH/CMB/CMH and underlying etiology:
HV/CAA; (3) main research methods: imaging vs. biochemical
and techniques used to assess BBB dysfunction and hemorrhage
occurrence; (4) markers used to define BBB dysfunction and
hemorrhage, if possible including hemorrhage location; (5)
studied sample (percentage with hemorrhage) and control group
(size, age, and sex); (6) main outcomes (numeric where possible).
To quantify the strength of group differences (when possible),
the standardized mean difference (Hedges’ G) was computed for
human observational studies that quantified and reported amean
and SD of the BBB disruption marker for the studied sample and
control group. We followed the PRISMA guideline (Preferred
Reporting Items for Systematic Reviews and Meta-Analyses).
Study Quality Assessment
We assessed the methodological quality of the individual human
case-control studies according to the Newcastle-Ottawa Scale
(NOS) (23), and the quality of the studies with a case-series
design with an adapted version of the NOS (Table S1) (24).
Methodological quality of the individual animal studies was rated
using an adapted version of the CAMARADES scale (Table S2)
(25).
RESULTS
Our search yielded a total of 2,750 publications, of which 26
studies were relevant. Ten studies described a total of 79 animals
in which cSVD-related hemorrhage was modeled, and 54 animals
serving as controls. Sixteen studies described 688 human patients
with ICH and CMBs, and 1,080 controls without ICH and CMBs
(Figure 1). The methodological quality of all studies was assessed
and varied from poor (2/9) to good (9/9) (Tables S1, S2).
Animal Studies
Of the ten studies in animals, four assessed BBB dysfunction in
HV-related ICH (n = 32), and six assessed CAA-related ICH
(n= 47) (Tables 1, S3) (26–35).
All four studies of HV-related hemorrhage found evidence
for BBB dysfunction (26–29). One of these demonstrated
increased vascular permeability to a gadolinium-based contrast
agent on MRI that preceded ICH in time in three out of
seven (42%) stroke-prone spontaneously hypertensive rats (SP-
SHR) that developed ICH (26). The location of BBB leakage
corresponded to the site of the ICH. The second study assessed
proteomic changes in microvessels of transgenic (hCETP)
hyperlipidemic Dahl salt sensitive hypertensive rats and their
non-transgenic normolipidemic littermates (27). Based on age,
sex and transgenic status the rats were divided into being
stroke-prone (n = 11) and non-stroke prone (n = 15). Stroke
susceptibility in the pre-stroke stage was associated with an
increase in twelve proteins, of which nine were related to
BBB integrity. A third study demonstrated CMHs and bilateral
increased extravasation of the plasma protein immunoglobulin
G (IgG) with co-localized matrix metalloproteinase-9 (MMP-
9) immunoreactivity in the external capsule, corpus callosum,
and internal capsule in SP-SHR with unilateral carotid artery
occlusion and on a stroke-permissive diet (Japanese-style) (n= 5)
compared with sham-operated SP-SHR on a regular diet (n = 5)
(28). The fourth study identified deposition of IgG in vessel
walls within the cortex, basal ganglia, hippocampus and corpus
callosum of SP-SHR (n = 9) that preceded the formation of
CMHs (29).
Four of six studies examining animal models of CAA found
evidence for BBB dysfunction (30–35). One study identified
fibrinoid extravasation and CMHs in some CAA affected vessels
in the forebrain cortex of old squirrel monkeys with CAA (n= 4),
but not in a young squirrel monkey with no CAA (n = 1)
(30). A second study demonstrated BBB leakage in the form
of increased albumin and IgG plasma protein extravasation in
TG2576 (APP/Sw) (n = 10) and bigenic PSAPP (APP/Sw X
PS1M146L) (n= 6) mice with increased CMH load compared with
nontransgenic controls (n = 6) (31). The third study showed
MMP-9 immunoreactivity in 30% of CAA affected vessels and
in 79% of vessels with CMHs in old Tg2576 mice (n = 4)
while no MMP-9 immunoreactivity could be detected in young
Tg2576 (n = 2) or old wild type mice (n = 2) (32). The fourth
study found evidence for BBB dysfunction in heterozygous TGF-
β mice (n = 5) with CMHs on histopathology in the form
of a 12% increase in BBB permeability to a gadolinium-based
contrast agent compared with wild type littermates (n = 5) (33).
In contrast, another MRI study did not find any difference in
BBB leakage of gadolinium-based contrast material in transgenic
arcAβ mice with higher CMB frequencies (n = 15) compared
with wild type controls (n = 15) (34). The sixth study found no
evidence for leakage of horseradish peroxidase or Trypan blue
dye at sites beyond the vicinity of the hemorrhage in transgenic
APP23 mice (n= 3) and wild type littermates (n= 3) (35).
Human Studies
Of the sixteen included studies, one assessed BBB dysfunction in
HV-related ICH (n= 82) (36) six in CAA-related ICH (n= 117)
(37–42), and nine did not specify the underlying etiology of the
ICH (n= 489; Tables 2A, 2B, S4) (44–52).
One study examined HV-related ICH patients post-mortem
(n = 82) and reported endothelial integrity of cerebral arteries,
arterioles and capillaries, and as such found no evidence for BBB
dysfunction (36).
Of six studies that assessed CAA-related BBB dysfunction,
five studies found evidence for ICH-associated BBB dysfunction.
Three studies assessed BBB abnormalities as defined by altered
gelatinase levels in cortical vessels (38, 42), cerebral tissue (38),
plasma (38), and CSF (41), in patients with CAA. The first
study identified an increased percentage of MMP-2 positive
cortical vessels in moderately to severely Aβ affected vessels
from CAA patients compared with not to mildly affected
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FIGURE 1 | Flow chart of study selection. After title and abstract examination of 2,750 publications, 2,505 papers were excluded, leaving 245 papers to be read. Of
these, 218 papers did not meet the inclusion criteria [hemorrhage was induced artificially in animals (n = 144) or caused by factors other than cSVD (n = 17), BBB
dysfunction was only assessed in the peri-hematomal region (n = 33), or a direct measure for BBB leakage was absent (n = 20)], and four papers were excluded
because we could not translate them (one Polish and three Chinese). One duplicate dataset was discovered, so we only included the first publication. The remaining
26 papers were deemed eligible for inclusion. No additional papers were included after screening the reference lists of the included articles.
cortical vessels of the same patients (n = 6) and cortical vessels
of non-CAA controls (n = 3). No differences were found
for MMP-9. In the same study, MMP-2 and MMP-9 plasma
concentrations were measured in vivo but their levels did not
differ between CAA-related ICH (n= 33) and non-CAA controls
(n= 21). Besides, post-mortem tissue pro-MMP-2 and pro-MMP-
9 protein content was not different between individuals with
CAA-related ICH (n = 4) and non-CAA controls (n = 3)
(38). A second study found that 79% of CAA-affected vessels
were immunopositive for MMP-9 in CAA cases with (n = 4)
and without (n = 6) Alzheimer disease (AD), while only 5%
of control vessels were immunopositive for MMP-9 (n = 4
non-CAA control cases). Moreover, MMP-9 immunoreactivity
in the vessel wall was significantly increased in CAA vessels
at late stages (stages 3 and 4) compared with early stages
(stages 0–1), but no MMP-9 differences were observed between
non-affected vessels of CAA patients and non-CAA controls
(42). A third study found lower MMP-9 concentrations in CSF
of individuals with AD or vascular dementia (VaD) with lobar
CMBs (n= 32) compared with AD or VaD patients without lobar
CMBs (n= 27) and cognitively normal controls (n= 26). Tissue
inhibitors of matrix metalloproteinase (TIMP-2) CSF levels were
elevated in AD/VaD without CMBs (n = 27) compared with
cognitively normal controls (n = 26) and AD/VaD patients with
CMBs (n = 34), but no differences were found for TIMP-1
(41).
Two other studies examining CAA patients found evidence
for BBB dysfunction. The first study in the form of decreased tight
junction protein (TJP) occludin immunoreactivity in capillaries
from the frontal cortex, and reduced levels of TJPs occludin and
ZO-1 in leptomeningeal vessels as measured with Western blot
analyses in patients with CAA (n = 9) compared with non-CAA
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TABLE 1 | Overview animal studies.
Study cSVD
type
Hemorrhage
type
Study
design
Study sample (n) Marker of BBB dysfunction Main outcome Evidence for
BBB dysfunction
Lee et al. (26) HV ICH L, P, IV SP-SHR (7) Leakage of contrast agent Vascular permeability was increased
in 42% of rats with ICH before ICH
incidence
Yes
Bergerat et al.
(27)
HV ICH CS, P, PM Transgenic (hCETP)
and non-transgenic
stroke-prone Dahl-S
rats (11)
Proteomic changes Proteomic changes specific to
increased stroke susceptibility profile
are associated with BBB dysfunction
Yes
Jalal et al. (28) HV CMB CS, P, PM SP-SHR with UCAO
and on a Japanese diet
(5)
Plasma protein extravasation and
altered gelatinase expression
IgG leakage and increased MMP-9
expression co-localized with CMBs
Yes
Schreiber
et al. (29)
HV CMB CS, P, PM SP-SHR (9) Plasma protein deposition in
vessel wall
CMBs occur for the first time several
weeks after IgG vessel wall deposition
can be detected
Yes
Elfenbein
et al. (30)
CAA CMB CS, P, PM Aged squirrel monkeys
(4)
Plasma protein extravasation Fibrinoid extravasation is apparent in
animals with severe CAA and CMBs
Yes
Kumar-Singh
et al. (31)
CAA CMB CS, P, PM APP-sw transgenic
mice (10) and PSAPP
transgenic mice (n = 6)
Plasma protein extravasation Transgenic animals presented with
more CMBs and with more albumin
and IgG leakage
Yes
Lee et al. (32) CAA CMB CS, P, PM Transgenic APP-sw
mice (4)
Altered gelatinase expression MMP-9 expression was found in 30%
of amyloid-laden vessels and in 79%
of vessels with CMBs
Yes
Lifshitz et al.
(33)
CAA CMB CS, P, IV Transgenic TGF-β1
mice (5)
Leakage of contrast agent 12% increase in transgenic mice with
CMBs compared with wild type mice
Yes
Klohs et al.
(34)
CAA CMB L, P, IV Transgenic arcAβ mice
(15)
Leakage of contrast agent No difference between animals with
and without CMBs
No
Winkler et al.
(35)
CAA ICH+CMB CS, P, PM Transgenic APP-23
mice (3)
HRP/Trypan blue leakage in
cerebral tissue
No obvious leakage unless acute
bleeding was present
No
HV, hypertensive vasculopathy; CAA, cerebral amyloid angiopathy; ICH, intracerebral hemorrhage; CMB, cerebral microbleed; L, longitudinal; CS, cross-sectional; P, prospective; R,
retrospective; n/a, not answerable; PM, post-mortem; IV, in vivo; MMP, matrix metalloproteinase; SP-SHR, stroke-prone spontaneously hypertensive rats; IgG, immunoglobulin G;
UCAO, unilateral carotid artery occlusion; Dahl-S, Dahl salt-sensitive; APP, amyloid precursor protein.
controls (n = 10) (40). The second study used MRI to identify
gadolinium-based contrast agent leakage through the BBB on T1-
weighted images in a subset (n= 2 out of 19, 11%) of individuals
with CAA (37). In contrast, one study in patients with Alzheimer
disease with (n = 6) and without (n = 12) lobar CMBs found no
difference in p-glycoprotein expression (39).
Seven out of nine studies found evidence for BBB dysfunction
without distinguishing between HV- and CAA-related ICH.
Two of these found gadolinium-based contrast agent leakage
on MRI in 48% to 85% of patients (44, 45). The third
and fourth study used an iodine-based contrast agent to
measure BBB dysfunction with computed tomography. One of
these studies found increased permeability in the hemisphere
ipsilateral to the ICH relative to the contralateral hemisphere
(n = 53) within 26 h after symptom onset (46). In contrast,
the other study could not identify any difference in BBB
permeability between the hemisphere ipsilateral to the ICH and
the contralateral hemisphere (n = 54) between 24 and 72 h
after ICH onset (47). No control group was included in any
of these imaging studies. The fifth study described decreased
immunoreactivity of TJP claudin-1 on visually inspected sections
of basal ganglia tissue of patients with ICH (n = 9) compared
to sections of non-ICH controls (n = 10) (51). The sixth
study found increased CSF/serum albumin ratios in memory
clinic patients with multiple CMBs (n = 118), but not in
memory clinic patients with single CMBs (n = 96) compared
to those without CMBs (n = 825) (49). The seventh study
demonstrated increased vascular endothelial growth factor levels
in serum of AD patients with CMBs (n = 47) vs. AD
patients without CMBs (n = 99) (48). The eighth study
showed increased BBB dysfunction in the form of an increased
CSF/serum albumin ratio in patients with cognitive decline
with CMBs (n = 15) compared with patients with cognitive
decline but no CMBs (n = 13) (50). In contrast, the last
study could not identify any difference in BBB dysfunction
measured as CSF/serum albumin ratios between AD patients
with CMBs (n = 26) and AD patients without CMBs (n = 26)
(52).
The effect size of the group difference between the studied
sample and control sample of 5 human studies that quantified
the mean (SD) of markers of BBB dysfunction is visualized in
Figure S1. Three of the five studies report no difference in BBB
dysfunction between patients and controls in these quantified
measurements, which is in line with the results described in
the previous paragraphs (38, 39, 52). However, one of these
studies did find a difference between patients and controls
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when using another measurement method which we could not
include in our figure (percentage of MMP-2 positivity within
and around vessels in moderately to severely Aβ affected vessels
from ICH patients) (38). Because of the large heterogeneity of
markers used to assess BBB dysfunction and the differences
in control samples that were used, we did not proceed to
meta-analysis.
DISCUSSION
In this systematic review we found support for a possible role of
BBB dysfunction in the pathophysiology of cSVD-related ICH
and CMBs/CMHs in 20 out of 26 studies. We found evidence
supportive of a role for BBB dysfunction in both animal and
human studies, and in HV-related ICH or CMBs/CMHs and
CAA-related ICH or CMBs/CMHs. Signs of BBB disruption
were found in studies with in vivo BBB assessment, including
MRI, CT and CSF/serum analysis, as well as in studies using
post-mortem histopathological or proteomic analyses to assess
BBB dysfunction. Based on the available observations in these
studies, we postulate that multiple pathways may contribute to
BBB dysfunction, which may in part be caused by the underlying
pathology. Degradation of the basement membrane, loss of tight
junction proteins, and plasma protein deposition within the
vessel wall probably contribute to vessel wall instability. These
vessel changes may interfere with the vessels’ autoregulatory
ability to respond to changes in blood pressure, which may in
turn predispose to rupture in the context of hypertension or
CAA. Interestingly, animal studies suggest that BBB dysfunction
precedes ICH or CMB/CMH occurrence, but it remains unclear
whether this relationship is causal.
The studies included in this review used a wide variety of
methods to, presumably, measure BBB dysfunction. Although
we reported differences in study quality according to standard
assessment scales, we cannot compare the sensitivity and
specificity of each individual BBB assessment approach. As a
result, and because of the wide variety of the included animal
models and types of patients, it is difficult to extrapolate the
findings in this review outside the context of each individual
study. This heterogeneity is also reflected by the variation in
effect sizes of differences between cases and controls that we
computed for five human studies (Figure S1). Somemarkers may
be more strongly associated with hemorrhagic brain pathology
than others, which may explain the relatively large effect size
of the study by Zhang et al. (48). In addition, the validity of
the markers that were identified by the studies as measuring
BBB dysfunction remains unclear. For example, multiple studies
measured the CSF-albumin ratio as a proxy for BBB dysfunction,
but previous research has suggested that this marker is more
strongly associated with blood-CSF-barrier dysfunction at the
level of the choroid plexus rather than with BBB dysfunction
(53–56).
Although the majority of studies (20 out of 26) found support
for the possibility that blood-brain barrier dysfunction may play
a role in cSVD-related intracerebral hemorrhage, there were
six studies that did not find this association. Two of the four
human studies that did not find indications for BBB dysfunction
compared AD patients with CMBs to AD patients without CMBs
(39, 52). A possible source of bias in these studies is latent
presence of HV and CAA in AD without CMBs, such that the
control AD group also has BBB dysfunction to some degree.
Methodological issues, such as low sensitivity of the marker of
BBB dysfunction and statistically underpowered analyses due to
restricted sample size may also have played a role.
Animal studies are considered a valuable tool to study the
temporal relationship of pathophysiological processes. However,
themajority of animal studies included in this review did not have
a longitudinal but a cross-sectional design. Most of the cross-
sectional studies found BBB abnormalities in concurrence with
the presence of CMHs (28, 30–33, 35), but some observed BBB
changes in animal models of HV or CAA before they reached
the age at which hemorrhages typically occur (27, 29). Only
two studies assessed the relation between BBB dysfunction and
occurrence of CMBs or ICH longitudinally. One study did not
identify BBB alterations in relation to CMBs (34), while the other
study was able to monitor ICH development and preceding co-
localized BBB dysfunction in vivo (26). A recent case-report of a
patient with probable CAA showed development of a new CMB
exactly at the location of gadolinium leakage on 7T MRI (11).
These findings, although the evidence is limited, suggest that BBB
dysfunction may precede cerebral hemorrhage.
Strengths of this review include the systematic literature
search and inclusion of both human and animal studies, which
allowed us to summarize the evidence of BBB dysfunction
assessed by a variety of methods and in multiple and variable
cohorts of cSVD related ICH patients and animals. In addition,
the inclusion of animal studies allowed interpretations in terms
of disease mechanisms and could provide a first indication of
the temporal relationship between BBB dysfunction and cerebral
hemorrhage.
Our systematic review also has limitations. The title and
abstract screening were performed by a single author (W.M.F.)
which may have resulted in some form of bias with regard to
the study selection. However, in case of uncertainty, the abstract
or text was discussed with a second author (C.J.M.K.). Many
of the included studies had a relatively small sample size, eight
studies lacked a control group, and results were not quantified in
five studies. Some of the CMBs rated on MRI, especially beyond
the context of CAA, may correspond to other lesion types, such
as microinfarcts with a hemorrhagic component, which may
bias the results (57). Furthermore, caution is warranted since
negative findings in general and presence of hemorrhage in
cSVD animal models are likely to be underreported, leading to
publication bias and selective reporting within studies. Moreover,
results on various transgenic animal models with CAA were
reported but these models may not be specific to cSVD since
the animals also exhibit AD pathology, and several studies
examined animals at a relatively young age. Although the
findings in animal models are valuable for understanding disease
physiology, these models do not perfectly mimic human disease.
While the human studies suggest possible involvement of BBB
dysfunction in ICH or CMB formation, their cross-sectional
nature hampers the ability of making any causal inferences.
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We only identified one human study that assessed HV-related
ICH, so future studies on this topic are warranted. Finally,
although previous work has suggested that CMBs are predictors
of future ICH (19), it is not yet clear whether these two types
of hemorrhage constitute similar pathophysiological foundations
(58).
To increase insights into the role of BBB dysfunction
in the pathophysiology of ICH and CMBs/CMHs, dedicated
prospective studies of animal models of CAA and HV with
serial in vivo neuroimaging examinations combined with post-
mortem BBB assessment are needed. This should be combined
with longitudinal in vivo monitoring of BBB integrity in various
cohorts and post-mortem assessments in humans. Such studies
are, unfortunately, hard to establish because it will be difficult
to achieve a reasonable sample size. Besides the role of BBB
dysfunction in vessel rupture, its involvement in other cSVD-
associated brain injury types and cognitive decline should
be considered as well. Previous studies have already linked
BBB dysfunction to brain atrophy, lacunar infarcts, WMH
pathogenesis and cognitive impairment (59–62), emphasizing
the possible clinical relevance of BBB dysfunction beyond ICH
pathogenesis. The development of more sensitive methods to
measure and localize BBB dysfunction in vivo may identify
individuals at risk for ICH and other types of cSVD-related
brain injury. Importantly, supporting BBB integrity may be a
potential target in developing strategies to prevent ICH and
CMBs/CMHs in the context of cSVD, and monitoring BBB
dysfunction could be a method to evaluate the efficiency of
treatment strategies.
CONCLUSION
This systematic review suggests that BBB dysfunction plays
a role in the pathophysiology of cSVD-related ICH and
CMBs/CMHs. The hypothesis that BBB dysfunction precedes
ICH or CMB/CMH formation needs confirmation in larger
longitudinal studies in humans.
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